Susquehanna Fundamental Investments LLC Purchases New Holdings in Moderna, Inc. (NASDAQ:MRNA)

Susquehanna Fundamental Investments LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 385,677 shares of the company's stock, valued at approximately $16,036,000. Susquehanna Fundamental Investments LLC owned approximately 0.10% of Moderna as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter worth about $37,000. Venturi Wealth Management LLC lifted its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in Moderna during the fourth quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MRNA has been the topic of several recent analyst reports. Bank of America reduced their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. JPMorgan Chase & Co. dropped their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Friday, March 21st. Leerink Partners dropped their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research note on Thursday, January 16th. Finally, William Blair reissued a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Moderna has an average rating of "Hold" and an average price target of $58.70.

Moderna Stock Performance

Moderna stock traded up $0.36 during midday trading on Tuesday, reaching $27.82. 5,238,914 shares of the company's stock were exchanged, compared to its average volume of 7,367,871. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The firm has a market cap of $10.76 billion, a price-to-earnings ratio of -3.00 and a beta of 2.23. The stock's 50-day simple moving average is $30.03 and its 200 day simple moving average is $38.15.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.